Chugai Pharmaceutical (CHGCF) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you very much for taking time out of your very busy schedules to attend our first quarter FY2026 earnings call. My name is Miyata from Corporate Communication and IR department, and I'll be serving as the moderator today. Thank you for your kind attention. The session will be conducted via Zoom webinar. We will proceed according with the agenda shown on page 3 of the presentation material. The briefing will be conducted in Japanese, but we will have simultaneous interpretation in English also available. Please click the interpretation icon at the bottom of your screen and select either Japanese or English. for your preferred language. Questions will be taken together after all the presentations have been concluded. The Q&A session is scheduled for approximately 30 minutes. Please note that participants' microphones will remain muted during the presentation. First, Dr. Okuda to provide an overview of the first quarter of FY2026. I am Okuda, President and CEO I would like to give an overview of the first quarter of FY2026. Please refer to slide 5 in the material at hand. In the first quarter of FY2026, both domestic and overseas product sales progressed steadily, resulting in both increase in revenue and profit. Growth was driven mainly by Libra exports to Roche, as well as increased NEM Lubio exports to and higher low-income from Kaldurma. As a result, compared with the same period last year, revenue increased by 11.5%, operating profit by 17.1%, and quarterly profit by 19.6%. As such, first quarter got off to a smooth start in line with our initial expectations. Details of the revenue will be covered on the next slide, slide 6. This shows the year-on-year changes in revenue compared with the same period last year. Revenue grew by 33.2 billion yen, up 11.5%. I w...